ArticlePloS one2026
Statin prescribing patterns in cardiovascular risk management among outpatients with type 2 diabetes: Real-world practices at a Vietnamese general hospital.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the current prescribing patterns of statin therapy among outpatients with type 2 diabetes at Friendship Hospital, with a focus on alignment between treatment intensity with cardiovascular risk factors.
methodsA retrospective cohort study was conducted at Friendship Hospital from December 2022 to December 2023. Patient aged 40-75 years with type 2 diabetes mellitus who attended follow-up visits were included using stratified random sampling by treatment department. Clinical data were extracted from medical records to assess cardiovascular risk based on the 2023 American Diabetes Association guideline and to document statin use, intensity, treatment continuity and related factors. Multivariate logistic regression was performed to identify factors associated with whether or not patients were prescribed statins.
resultsAmong 407 patients, 30.5% were classified as having established ASCVD, 55.6% as having high cardiovascular risk, and 99.8% of patients were eligible for indication of high intensity statin. Despite this, none received high-intensity statin. Most patients (77.4%) were prescribed moderate-intensity statins, 8.6% received low-intensity statins, and 14.0% were not prescribed any statin. A total of 58.5% of patients received uninterrupted statin prescriptions over one year, whereas 54.3% underwent changes in statin intensity during the follow-up period. Statin prescription (versus non-prescription) was significantly influenced by the treatment department, ASCVD status, and the presence of dyslipidemia (p < 0.05).
conclusionAlthough statin use was common, the intensity and continuity of treatment were often inconsistent with cardiovascular risks. The absence of high-intensity statin prescriptions in a population largely at very high risk may limit the potential benefits of lipid-lowering therapy. These findings highlight the need to strengthen adherence to guideline-directed statin therapy in the management of type 2 diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.